Simcere Pharmaceutical Group Ltd. (2096.HK,SMHGF), on Monday, announced that a subsidiary, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., has entered into an exclusive licensing agreement with Ipsen S.A. (IPN.PA,IPSEY) for SIM0613, an LRRC15-targeting antibody-drug conjugate.
The company is eligible to receive up to $1.06 billion under the deal, comprising a $45 million upfront payment and additional development, regulatory, and commercial milestone payments.
Under the agreement, Ipsen receives exclusive global rights outside Greater China to develop, manufacture, and commercialize SIM0613.
The drug candidate was developed by Jiangsu Zaiming.
The agreement was signed on December 19 and includes tiered royalties on net sales.
Simcere Pharma is currently trading 2.29% lesser at HKD 12.810 on the Hong Kong Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.